A new anthrax vaccine is under development that could more quickly provide protection, require fewer doses, and be more cost-effective than the current vaccine, according to the HHS.
Related: The Immunization Community
The new vaccine, NuThrax, is a modified formulation of BioThrax, which is stored in the CDC’s Strategic National Stockpile. Studies to date suggest that 2 doses of NuThrax are enough to protect against anthrax compared with 3 doses of BioThrax.
Related: Jonathan Woodson on Military Health Readiness
The National Institute of Allergy and Infectious Disease and the DoD sponsored early development of NuThrax, which included both nonclinical studies and phase 1 and 2 clinical studies. Next steps include phase 3 studies with larger groups. Emergent BioSolutions of Gaithersburg, Maryland, which makes BioThrax, will also be responsible for developing NuThrax.
Related: VA and Walgreens Pair up to Offer Free Flu Shots
“Anthrax remains a national health security threat. If it works, this vaccine may help achieve better preparedness at a lower cost,” said Robin Robinson, PhD, director of the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at HHS, which will provide funding and technical assistance.